zoledronic acid has been researched along with Carcinoma, Ovarian Epithelial in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cabillic, F; Catros, V; Daniel, P; Dessarthe, B; Henno, S; Jaffre, I; Lavoué, V; Levêque, J; Thedrez, A | 1 |
1 other study(ies) available for zoledronic acid and Carcinoma, Ovarian Epithelial
Article | Year |
---|---|
A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; CD3 Complex; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Diphosphates; Diphosphonates; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imidazoles; Interferon-gamma; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prognosis; Survival Analysis; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Treatment Outcome; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2013 |